Loading resource…

Queen Square Institute of Neurology, University College London
Parkinson's disease is characterized by the abnormal aggregation of α-synuclein and its spread across various brain regions. The document reviews biochemical studies and cellular dysfunctions, including mitochondrial and lysosomal abnormalities, that contribute to the disease's progression. It also emphasizes the importance of immune responses and the development of biomarkers for patient stratification in clinical trials. Despite the absence of disease-modifying treatments, the findings provide a foundation for future neuroprotective therapies.
No account needed